CNBC Television published this video item, entitled “We believe the risk-benefit profile for our Alzheimer’s drug is acceptable, says Eisai U.S. CEO” – below is their description.
Ivan Cheung, Eisai U.S. CEO, joins ‘Closing Bell’ to discuss the results of Eisai’s experimental Alzheimer’s phase three trial, the side effects associated with the Alzheimer’s drug and more.
CNBC Television YouTube Channel
Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.